The week in industry: US FDA approves first FGFR kinase inhibitor
This week: Enesi Pharma (Abingdon, UK) enter into partnership to develop new vaccines against influenza, US FDA accept application from Norvatis (Basel, Switzerland) to expedite review of drug to treat wet age-related macular degeneration and Phase I/IB trial initiated for patients with advanced cancer.
Please sign in or register for FREE
Sign in to RxNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Future Medicinal Chemistry FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RxNet account also gives you access to communities on regenerative medicine, real-world evidence and 3D printing in medicine. Find out more>>